logo
Plus   Neg
Share
Email

RF Monolithics To Be Purchased By Murata Electronics North America For $1.78/Shr

RF Monolithics Inc. (RFMI) reached a definitive agreement to be acquired by Murata Electronics North America, Inc. for $1.78 per share to holders of RFM common shares, representing an 80% premium over the Nasdaq closing price as of April 12, 2012. The acquisition may complete in the third calendar quarter of 2012.

David Kirk, President and CEO of Murata Electronics North America Inc., the Regional Headquarters of Murata Americas said, "RFM's proven success in developing business in the healthcare, energy and industrial markets complements Murata's growth strategy. Additionally, leveraging RFM's expertise in design and development of production-ready RF modules, SAW based and RFIC short-range radios, stand-alone radio systems and platforms for M2M applications will enable Murata to increase the value of the wireless module solutions delivered to Murata's existing and future customers in the global marketplace."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT